

Freedom of Information Request	FOI 22-489	24 th October 2022
--------------------------------	------------	-------------------------------

- 1. Is bevacizumab (Avastin®) available for use in the treatment of wet age-related macular degeneration (AMD) in your health board (and/or in relation to any other eye conditions). This is an unlicensed use of the drug. In 2018, the then Health Minister said its use for wet AMD in Wales would be a decision for health boards (see attached statement).**

Bevacizumab (Avastin) was not made available for routine use in wet-AMD within the Health Board.

- 2. If bevacizumab was available in your health board for this use (and/or in relation to any other eye conditions) but this is no longer the case, please could you provide details of the date it ceased to be available and reasons behind this decision.**

Whilst the Health Board never made bevacizumab pre-filled syringes in it's production unit it has occasionally made a supply of both the vials (100mg) and commercially sourced pre-filled syringes (1.25mg in 0.05ml) to ophthalmic areas within the Health Board. These supplies are summarised below:

2020

Single 100mg vial supplied to RGH eye outpatient department.

Single 1.25mg pre-filled syringe supplied to RGH Ophthalmic theatre.

Single 1.25mg pre-filled syringe supplied to YYF Lucentis clinic.

2021

2 x 1.25mg pre-filled syringes supplied to RGH Eye Day Unit.

2022

Single 100mg vial supplied to RGH Ophthalmic theatre.

Please note the Health Board is unable to confirm if these quantities were used use for wet-AMD or other ophthalmic uses. The Health Board's procurement team have advised that 100mg bevacizumab vials remain available for ordering.